Artelo Biosciences Inc ARTL 深 沪
已收盘 03-27 16:00:00 美东时间
10.54
+7.350
+230.41%
华盛通- 最 高19.9099
- 今 开7.99
- 成交量 8246.97万股
- 最 低 7.45
- 昨 收 3.19
- 总市值 746.55万
- 52周最高 85.80
- 市盈率 静 --
- 换手率 11643.33%
- 52周最低 2.955
- 委 比 99.71%
- 总股本 70.83万
- 历史最高 1350.00
- 量 比 22.22
- 振 幅 390.59%
- 历史最低 3.15
- 每 手 1
- 风险率 12.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Artelo Biosciences Stock Soars After Withdrawing SEC Filing
Artelo Biosciences Inc. shares are trading higher Friday after withdrawing its SEC Registration Statement, citing no plan to sell securities.
03-27 21:36
Artelo Biosciences Expanding Use Of ART27.13 In Muscle Preservation For Glucagon-Like Peptide-1 Receptor Agonist Therapy Patients
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or
03-26 04:13
What's Going On With AIM ImmunoTech Stock Friday?
AIM ImmunoTech (AMEX: AIM) sees bullish momentum after final patent approval in Japan for its Ampligen-based oncology treatments.
03-20 23:07
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist
BUZZ-U.S. STOCKS ON THE MOVE-Tencent, Air Products, Protagonist Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 18 (Reuters) - Wall Street's main indexes were set to open l
03-18 21:11
Artelo Biosciences Enters Into Definitive Investigator-Initiated Study Agreement With BHSCT To Evaluate ART27.13 In Glaucoma Patients; First Patient Enrollment Expected In Q2 2026
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or
03-18 19:43
Artelo Biosciences Announces 3-For-1 Reverse Stock Split, Effective March 10
Artelo Biosciences, Inc. (NASDAQ:ARTL) ("Artelo" or the "Company"), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain,
03-06 21:08
BRIEF-Artelo Biosciences Announces Reverse Stock Split
BRIEF-Artelo Biosciences Announces Reverse Stock Split March 6 (Reuters) - Artelo Biosciences Inc ARTL.O : ARTELO BIOSCIENCES ANNOUNCES REVERSE STOCK SPLIT ARTELO BIOSCIENCES INC - BOARD APPROVES 3-FOR-1 REVERSE STOCK SPLIT OF COMMON STOCK Source text: ID:nGNX4lqFzl Further company coverage: ARTL.O
03-06 21:03
Artelo Biosciences approves 3-for-1 reverse stock split
Artelo Biosciences approves 3-for-1 reverse stock split Artelo Biosciences Inc. said its board approved a 3-for-1 reverse stock split, with shares set to trade on a split-adjusted basis on the Nasdaq Capital Market starting March 10, 2026. The move will consolidate every three shares into one, with
03-06 21:00
Artelo Biosciences Q4 EPS $1.38 Beats $(1.57) Estimate
Artelo Biosciences (NASDAQ:ARTL) reported quarterly earnings of $1.38 per share which beat the analyst consensus estimate of $(1.57) by 187.9 percent. This is a 119.66 percent increase over losses of $(7.02) per share
02-24 21:17
Artelo (ARTL) FY 2025 net loss totals USD 12.9 million
Artelo (ARTL) FY 2025 net loss totals USD 12.9 million Artelo Biosciences Inc. reported a FY 2025 net loss of USD 12.9 million, or USD 12.52 per basic and diluted share, alongside R&D expenses of USD 5.4 million and G&A expenses of USD 6.0 million. Cash and investments totaled USD 0.6 million as of
02-24 21:01
